Table 3.
Recovery (%) (±RSD) from application of optimized PCR, PLS and MCR–ALS models on the pharmaceutical formulations.
| Zerinolflu® |
Dequa-Flu® |
||||||
|---|---|---|---|---|---|---|---|
| Model | PAR | ASC | CHL | PAR | CAF | PHE | CHL |
| PCR | 97.01±3.25 | 99.04±4.99 | 101.00±2.21 | 103.07±2.74 | 104.64±4.77 | 96.80±6.25 | 96.00±5.28 |
| PLS1 | 107.37±2.23 | 98.95±3.25 | 106.93±5.32 | 101.96±2.01 | 98.32±3.25 | 105.79±5.57 | 111.46±6.21 |
| PLS2 | 100.06±3.60 | 101.06±3.11 | 90.74±4.25 | 94.29±3.25 | 102.02±5.21 | 94.53±7.25 | 92.52±8.96 |
| MCR-ALS | 98.87±2.57 | 101.38±5.25 | 106.12±7.25 | 98.93±4.35 | 96.19±6.34 | 111.57±8.22 | 102.02±9.57 |